RESUMEN
INTRODUCTION: Nitisinone used in alkaptonuria (AKU) can result in keratopathy due to strongly increased tyrosine levels. METHODS: This study aimed to investigate nutritional status and changes in plasma tyrosine and phenylalanine and urinary homogentisic acid (u-HGA) levels in 8 adult AKU patients (mean age, 56.3 ± 4.7 years) who were on tyrosine/phenylalanine-restricted diet together with 2 mg/day nitisinone. RESULTS: The treatment period was 23.4 ± 6.9 months. Daily dietary protein intake was restricted to 0.8-1.0 g/kg/day. Daily tyrosine intake was restricted to 260-450 mg/day for females and 330-550 mg/day for males. Tyrosine/phenylalanine-free amino acid supplements accounted for an average of 56.1% of daily protein intake. The following assessments were performed: anthropometric and plasma tyrosine level measurements every 2 months; ophthalmological examination every 6 months, and nutritional laboratory analyses and measurements of plasma amino acids and u-HGA once in a year. It was targeted to keep the plasma tyrosine level <500 µmol/L. The plasma tyrosine level was <100 µmol/L before the treatment in all patients and around a mean of 582.5 ± 194.8 µmol/L during the treatment. The diet was rearranged if a plasma tyrosine level of >700 µmol/L was detected. The u-HGA level before and after the 1st year of treatment was 1,429.3 ± 1,073.4 mmol/mol creatinine and 33.6 ± 9.5 mmol/mol creatinine, respectively. None of the patients developed keratopathy or experienced weight loss and protein or micronutrient deficiency. CONCLUSION: AKU patients should receive tyrosine/phenylalanine-restricted diet for reducing plasma tyrosine level to the safe range. Tyrosine/phenylalanine-free amino acid supplements can be safely used to enhance dietary compliance. Keratopathy and nutrient deficiency should be frequently monitored.
Asunto(s)
Alcaptonuria , Adulto , Alcaptonuria/tratamiento farmacológico , Alcaptonuria/metabolismo , Ciclohexanonas , Dieta , Proteínas en la Dieta , Femenino , Humanos , Masculino , Persona de Mediana Edad , Nitrobenzoatos , Fenilalanina , Tirosina/metabolismoRESUMEN
Alkaptonuria (AKU) is caused by homogentisate 1,2-dioxygenase deficiency that leads to homogentisic acid (HGA) accumulation, ochronosis and severe osteoarthropathy. Recently, nitisinone treatment, which blocks HGA formation, has been effective in AKU patients. However, a consequence of nitisinone is elevated tyrosine that can cause keratopathy. The effect of tyrosine and phenylalanine dietary restriction was investigated in nitisinone-treated AKU mice, and in an observational study of dietary intervention in AKU patients. Nitisinone-treated AKU mice were fed tyrosine/phenylalanine-free and phenylalanine-free diets with phenylalanine supplementation in drinking water. Tyrosine metabolites were measured pre-nitisinone, post-nitisinone, and after dietary restriction. Subsequently an observational study was undertaken in 10 patients attending the National Alkaptonuria Centre (NAC), with tyrosine >700 µmol/L who had been advised to restrict dietary protein intake and where necessary, to use tyrosine/phenylalanine-free amino acid supplements. Elevated tyrosine (813 µmol/L) was significantly reduced in nitisinone-treated AKU mice fed a tyrosine/phenylalanine-free diet in a dose responsive manner. At 3 days of restriction, tyrosine was 389.3, 274.8, and 144.3 µmol/L with decreasing phenylalanine doses. In contrast, tyrosine was not effectively reduced in mice by a phenylalanine-free diet; at 3 days tyrosine was 757.3, 530.2, and 656.2 µmol/L, with no dose response to phenylalanine supplementation. In NAC patients, tyrosine was significantly reduced (P = .002) when restricting dietary protein alone, and when combined with tyrosine/phenylalanine-free amino acid supplementation; 4 out of 10 patients achieved tyrosine <700 µmol/L. Tyrosine/phenylalanine dietary restriction significantly reduced nitisinone-induced tyrosinemia in mice, with phenylalanine restriction alone proving ineffective. Similarly, protein restriction significantly reduced circulating tyrosine in AKU patients.
Asunto(s)
Alcaptonuria/dietoterapia , Alcaptonuria/tratamiento farmacológico , Ciclohexanonas/farmacología , Dieta con Restricción de Proteínas , Nitrobenzoatos/farmacología , Tirosinemias/dietoterapia , Alcaptonuria/metabolismo , Animales , Femenino , Humanos , Masculino , Ratones , Fenilalanina/metabolismo , Tirosina/metabolismo , Tirosinemias/metabolismoAsunto(s)
Alcaptonuria/tratamiento farmacológico , Ensayos Clínicos como Asunto/métodos , Ensayos Clínicos como Asunto/normas , Ensayos de Uso Compasivo , Enfermedades Raras/tratamiento farmacológico , Adolescente , Alcaptonuria/genética , Alcaptonuria/metabolismo , Alcaptonuria/orina , Animales , Autopsia , Niño , Ensayos Clínicos como Asunto/economía , Ciclohexanonas/farmacología , Ciclohexanonas/uso terapéutico , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Aprobación de Drogas , Determinación de Punto Final , Femenino , Ácido Homogentísico/metabolismo , Humanos , Lactante , Masculino , Ratones , Programas Nacionales de Salud , National Institutes of Health (U.S.) , Nitrobenzoatos/farmacología , Nitrobenzoatos/uso terapéutico , Estudios Observacionales como Asunto , Uso Fuera de lo Indicado , Producción de Medicamentos sin Interés Comercial , Enfermedades Raras/genética , Enfermedades Raras/metabolismo , Enfermedades Raras/orina , Ratas , Tamaño de la Muestra , Tirosina/metabolismo , Tirosinemias/tratamiento farmacológico , Tirosinemias/enzimología , Estados Unidos , United States Food and Drug Administration/legislación & jurisprudenciaRESUMEN
Alkaptonuria (AKU) is a rare genetic disease resulting in severe, rapidly progressing, early onset multi-joint osteoarthropathy. A potential therapy, nitisinone, is being trialled that reduces the causative agent; homogentisic acid (HGA) and in a murine model has shown to prevent ochronosis. Little is currently known about the effect nitisinone has on osteoarticular cells; these cells suffer most from the presence of HGA and its polymeric derivatives. This led us to investigate nitisinone's effect on chondrocytes and osteoblast-like cells in an in vitro model. Human C20/A4 immortalized chondrocytes, and osteosarcoma cells MG63 cultured in DMEM, as previously described. Confluent cells were then plated into 24-well plates at 4 × 10(4) cells per well in varying concentrations of nitisinone. Cells were cultured for 7 days with medium changes every third day. Trypan blue assay was used to determine viability and the effect of nitisinone concentration on cells. Statistical analysis was performed using analysis of variance, and differences between groups were determined by Newman-Keuls post-test. Analysis of C20/A4 chondrocyte and MG63 osteoblast-like cell viability when cultured in different concentrations of nitisinone demonstrates that there is no statistically significant difference in cell viability compared to control cultures. There is currently no literature surrounding the use of nitisinone in human in vitro models, or its effect on chondrocytes or osteoblast like cells. Our results show that nitisinone does not appear detrimental to cell viability of chondrocytes or osteoblast-like cells, which adds to the evidence that this therapy could be useful in treating AKU.
Asunto(s)
4-Hidroxifenilpiruvato Dioxigenasa/antagonistas & inhibidores , Alcaptonuria/tratamiento farmacológico , Condrocitos/efectos de los fármacos , Ciclohexanonas/uso terapéutico , Nitrobenzoatos/uso terapéutico , Osteoblastos/efectos de los fármacos , Línea Celular Tumoral , Ciclohexanonas/farmacología , Evaluación Preclínica de Medicamentos , Humanos , Nitrobenzoatos/farmacologíaRESUMEN
A 69-year-old woman presented with a 30-year history of lower back and large joint pain of the hips and shoulders. On examination blue-grey, pigmented macules were present over the cartilaginous portions of the ears and on the sclera. Past medical history included aortic stenosis. Urine homogentisic acid level was elevated, which is diagnostic for alkaptonuria. Alkaptonuria is an autosomal recessive disorder that results in deficiency of homogentisic acid oxidase and in the accumulation of homogentisic acid in connective tissue. Disease can result in blue-grey pigmentation of the cartilage, sclerae, face, and hands as well as severe arthropathy and cardiac valve disease. Treatment is limited at this time. Promising early reports of the use of nitisinone have prompted ongoing trials of this therapeutic agent.